GlaxoSmithKline PLC ADR (GSK)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from GSK's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from GlaxoSmithKline PLC ADR's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $24.7B | $29.3B | $30.3B | $31.4B | $32.7B |
| Net income | $4.4B | $15.0B | $4.9B | $2.6B | $5.7B |
| Free cash flow | $5.3B | $5.1B | $4.4B | $3.6B | $4.8B |
| EPS (diluted) | $1.08 | $3.66 | $1.20 | $0.62 | $1.39 |
| Operating margin | 17.6% | 21.9% | 22.2% | 12.8% | 24.3% |
Where the revenue comes from
Revenue by products, fiscal 2023.
Superinvestors who own GSK
From each investor's latest 13F filing (what a 13F shows). 9 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox |
Trimmed | $2.5B | 1.3% | Q2 2026 |
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | $1.3B | 0.78% | Q2 2026 |
| Charles Brandes Brandes Investment Partners, LP |
Added | $78M | 0.54% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $18M | 0.01% | Q2 2026 |
| Thomas Kahn Kahn Brothers Group |
Trimmed | $8M | 1.3% | Q2 2026 |
| Tweedy, Browne Tweedy, Browne Company |
Trimmed | $4M | 0.32% | Q2 2026 |
| Richard Pzena Pzena Investment Management |
Added | $1M | 0.00% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Trimmed | $1M | 0.01% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | $1M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by GlaxoSmithKline PLC ADR's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Dec 11, 2025 | Plc Gsk |
1,470,000 | $19.00 | $28M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when GSK trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are GlaxoSmithKline PLC ADR insiders buying the stock?
1 open-market insider purchase of GSK in the last 12 months, from SEC Form 4 filings.
Which superinvestors own GlaxoSmithKline PLC ADR?
9 of the superinvestors Investingly tracks hold GSK in their latest 13F, including Dodge & Cox, PRIMECAP Management, Charles Brandes.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.